Expression and Significance of BTLA and Its Ligand HVEM in Patients with Chronic Myelomonocytic Leukemia.
10.7534/j.issn.1009-2137.2020.01.010
- Author:
Chao LI
1
;
Su-Xia GENG
2
;
Min-Ming LI
2
;
Fang SU
3
;
Xiao-Mei CHEN
2
;
Cheng-Xin DENG
2
;
Xin HUANG
2
;
Pei-Long LAI
2
;
Jian-Yu WENG
2
;
Xin DU
4
Author Information
1. School of Medicine, South China University of Technology, Guangzhou 510006, Guangdong Province, China,Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, Guangdong Province, China.
2. Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, Guangdong Province, China.
3. Medical Research Center, SUN Yat-Sen Memorial Hospital of SUN Yat-Sen University, Guangzhou 510080, Guangdong Province, China.
4. School of Medicine, South China University of Technology, Guangzhou 510006, Guangdong Province, China,Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, Guangdong Province, China,E-mail: miyadu@hotmail.com.
- Publication Type:Journal Article
- From:
Journal of Experimental Hematology
2020;28(1):56-62
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the expression and significance of B and T lymphocyte weakening factor (BTLA) in patients with chronic myelomonocytic leukemia (CMML).
METHODS:Real-time PCR was used to detect the expression of BTLA and its ligand HVEM mRNA in 11 patients with chronic myelomonocytic leukemia and 11 normal donors. Flow cytometry was used to detect expression of BTLA and its HVEM on the cell surface of peripheral blood T lymphocytes and γδ T cells.
RESULTS:The median values of BTLA and its ligand HVEM mRNA expression in peripheral blood of patients with CMML were 0.009% and 559.4%, respectively, which were significantly lower than those of normal controls (0.053% and 1031%)(P<0.001). The expression level of BTLA and HVEM on cell surface of peripheral lymphocytes was not significantly different from that in normal controls (P=0.3031 and 0.2576), however, the proportion of peripheral blood T lymphocytes in patients with CMML (median: 37.73%) was significantly lower than that in controls (median 69.23%)(P=0.0005). The expression of BTLA on the surface of γδ T cells in peripheral blood of patients with CMML (median: 23.26%) was significantly lower than that of the controls (median: 52.64%) (P<0.05), and there was no significant abnormality in HVEM expression (P=0.2791).
CONCLUSION:The expression of BTLA and its ligand HVEM, the proportion of T lymphocytes and the expression of BTLA on the surface of γδ T cells in patients with CMML are reduced. The effects of these abnormalities on T cell function and prognosis and efficacy of patients need to be further observed.
